LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
QTTB
Q32 Bio Inc.
There isn't enough reported data to score QTTB yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
QTTB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Strong |
QTTB's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
QTTB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.4x | $8.37 | -5.2% |
| Current | 2.6x | $8.82 | — |
| Fair | 2.9x | $10.05 | +14% |
| Expensive | 4.8x | $16.68 | +89% |
Historical ranges are pointers, not guarantees.
QTTB has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
QTTB Forward outlook
There aren't enough analyst estimates for QTTB to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus QTTB down 75%.
QTTB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$14.07 | +$26.61 |
| Q2 2024 | -$22.87 | +$18.17 |
| Q1 2024 | -$32.43 | +$6.81 |
| Q4 2023 | -$35.10 | -$33.48 |
| Q3 2023 | -$40.68 | -$38.16 |
| Q2 2023 | -$41.04 | -$39.42 |
| Q1 2023 | -$39.24 | -$37.08 |
| Q4 2022 | -$1.62 | +$29.52 |
QTTB has returned to profit: it earned $3.46 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
QTTB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $354K | -56% |
| Q1 2023 | $802K | 0% |
| Q4 2022 | $802K | 0% |
| Q3 2022 | $802K | -52% |
| Q2 2022 | $802K | -63% |
| Q1 2022 | $802K | -97% |
| Q4 2021 | $802K | -18% |
| Q3 2021 | $1.7M | +196% |
QTTB's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -8705% | -5176 points |
| Q1 2023 | -3430% | +1260 points |
| Q4 2022 | -4301% | -108 points |
| Q3 2022 | -4098% | -2269 points |
| Q2 2022 | -3530% | -2133 points |
| Q1 2022 | -4691% | -4687 points |
| Q4 2021 | -4193% | -1152 points |
| Q3 2021 | -1828% | +3158 points |
QTTB's operating margin was −8705% last quarter, down 5176 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with QTTB at up 78%.
QTTB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.3M | +$6.1M |
| Q4 2025 | -$6.2M | +$5.3M |
| Q3 2025 | -$4.2M | +$15.4M |
| Q1 2025 | -$12.5M | +$2.1M |
| Q4 2024 | -$11.4M | +$10.1M |
| Q3 2024 | -$19.6M | +$5.4M |
| Q2 2024 | -$22.2M | +$1.4M |
| Q1 2024 | -$14.6M | +$11.7M |
QTTB has burned cash in almost every quarter: −$20M over the past year, against −$66M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over QTTB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
QTTB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +67% | +13.7M shares |
| 1 year | +178% | +21.8M shares |
| 3 years | +960% | +30.8M shares |
| 5 years | +984% | +30.9M shares |
| Available history | +1354% | +31.7M shares |
QTTB has 34M diluted shares, up 178% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
QTTB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.4x | Net Cash |
| Q2 2026 | -4.9x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
QTTB has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
QTTB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 17.7 | Oversold |
QTTB's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
QTTB PE vs Healthcare Sector
| Metric | QTTB | Sector median | Relative |
|---|---|---|---|
| PE | 2.6x | 26x | 90% below |
| PE % | 20 | 29 | 9 pts below |
QTTB has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over QTTB on trend strength, trading above more of its moving averages.
QTTB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.56 | 3% above |
| 20 week MA | $11.7 | 25% below |
| 50 week MA | $8.31 | 6.1% above |
| 100 week MA | $5.29 | 67% above |
| 200 week MA | $14.3 | 38% below |
QTTB's trend is mixed: it's above three of its five weekly moving averages, and 38% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
QTTB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.6 | $227.7 | -41% |
| 2021 | $227.7 | $74.5 | -67% |
| 2022 | $74.5 | $21.4 | -71% |
| 2023 | $21.4 | $10.9 | -49% |
| 2024 | $10.9 | $3.36 | -69% |
| 2025 | $3.36 | $3.20 | -4.8% |
| 2026 YTD | $3.20 | $8.82 | +176% |
QTTB has the edge over LLY on returns for 2026, with the stronger performance.